Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 민경환 | - |
dc.date.accessioned | 2019-12-07T21:19:44Z | - |
dc.date.available | 2019-12-07T21:19:44Z | - |
dc.date.issued | 2018-04 | - |
dc.identifier.citation | JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, v. 110, no. 4, page. 400-410, Article no. djx207 | en_US |
dc.identifier.issn | 0027-8874 | - |
dc.identifier.issn | 1460-2105 | - |
dc.identifier.uri | https://academic.oup.com/jnci/article/110/4/400/4443110 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/118493 | - |
dc.description.abstract | Background: Despite the benefit of endocrine therapy, acquired resistance during or after treatment still remains a major challenge in estrogen receptor (ER)-positive breast cancer. We investigated the potential role of histone demethylase retinoblastoma-binding protein 2 (RBP2) in endocrine therapy resistance of breast cancer.Methods: Survival of breast cancer patients according to RBP2 expression was analyzed in three different breast cancer cohorts including METABRIC (n = 1980) and KM plotter (n = 1764). RBP2-mediated tamoxifen resistance was confirmed by in vitro sulforhodamine B (SRB) colorimetric, colony-forming assays, and in vivo xenograft models (n = 8 per group). RNA-seq analysis and receptor tyrosine kinase assay were performed to identify the tamoxifen resistance mechanism by RBP2. All statistical tests were two-sided.Results: RBP2 was associated with poor prognosis to tamoxifen therapy in ER-positive breast cancer (P = .04 in HYU cohort, P = .02 in KM plotter, P = .007 in METABRIC, log-rank test). Furthermore, RBP2 expression was elevated in patients with tamoxifen-resistant breast cancer (P = .04, chi-square test). Knockdown of RBP2 conferred tamoxifen sensitivity, whereas overexpression of RBP2 induced tamoxifen resistance in vitro and in vivo (MCF7 xenograft: tamoxifen-treated control, mean [SD] tumor volume = 70.8 [27.9] mm(3), vs tamoxifen-treated RBP2, mean [SD] tumor volume = 387.9 [85.1] mm(3), P < .001). Mechanistically, RBP2 cooperated with ER co-activators and corepressors and regulated several tamoxifen resistance-associated genes, including NRIP1, CCND1, and IGFBP4 and IGFBP5. Furthermore, epigenetic silencing of IGFBP4/5 by RBP2-ER-NRIP1- HDAC1 complex led to insulin-like growth factor-1 receptor (IGF1R) activation. RBP2 also increased IGF1R-ErbB crosstalk and subsequent PI3K-AKT activation via demethylase activity-independent ErbB protein stabilization. Combinational treatment with tamoxifen and PI3K inhibitor could overcome RBP2-mediated tamoxifen resistance (RBP2-overexpressing cells: % cell viability [SD], tamoxifen = 89.0 [3.8]%, vs tamoxifen with BKM120 = 41.3 [5.6]%, P < .001).Conclusions: RBP2 activates ER-IGF1R-ErbB signaling cascade in multiple ways to induce tamoxifen resistance, suggesting that RBP2 is a potential therapeutic target for ER-driven cancer. | en_US |
dc.description.sponsorship | This work was supported by National Research Foundation of Korea (NRF) grants funded by the Korean government (No. 2015R1A2A1A10052578). | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | OXFORD UNIV PRESS INC | en_US |
dc.subject | HISTONE DEMETHYLASE RBP2 | en_US |
dc.subject | ESTROGEN-RECEPTOR BINDING | en_US |
dc.subject | H3K4 DEMETHYLASE | en_US |
dc.subject | TRANSCRIPTIONAL REPRESSION | en_US |
dc.subject | ENDOCRINE RESISTANCE | en_US |
dc.subject | GROWTH | en_US |
dc.subject | PROTEINS | en_US |
dc.subject | GENE | en_US |
dc.subject | ACTIVATION | en_US |
dc.subject | TUMORS | en_US |
dc.title | Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer | en_US |
dc.type | Article | en_US |
dc.relation.no | 4 | - |
dc.relation.volume | 110 | - |
dc.identifier.doi | 10.1093/jnci/djx207 | - |
dc.relation.page | 400-410 | - |
dc.relation.journal | JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | - |
dc.contributor.googleauthor | Choi, Hee-Joo | - |
dc.contributor.googleauthor | Joo, Hyeong-Seok | - |
dc.contributor.googleauthor | Won, Hee-Young | - |
dc.contributor.googleauthor | Min, Kyueng-Whan | - |
dc.contributor.googleauthor | Kim, Hyung-Yong | - |
dc.contributor.googleauthor | Son, Taekwon | - |
dc.contributor.googleauthor | Oh, Young-Ha | - |
dc.contributor.googleauthor | Lee, Jeong-Yeon | - |
dc.contributor.googleauthor | Kong, Gu | - |
dc.relation.code | 2018001789 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | kyueng | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.